BDO Wealth Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

BDO Wealth Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-237	Closed	-$44K	–	1165
2021 Q2	$44K	Sell	237 -9,131	-97%	-$1.57M	﹤0.01%	483
2021 Q1	$1.43M	Sell	9,368 -1,240	-12%	-$192K	0.17%	102
2020 Q4	$1.66M	Buy	10,608 +225	+2%	+$28.9K	0.23%	75
2020 Q3	$1.19M	Buy	10,383 +174	+2%	+$18.8K	0.19%	84
2020 Q2	$1.15M	Buy	10,209 +1,284	+14%	+$136K	0.2%	84
2020 Q1	$801K	Buy	8,925 +3,758	+73%	+$369K	0.16%	98
2019 Q4	$559K	Buy	5,167 +1,580	+44%	+$169K	0.14%	109
2019 Q3	$351K	Buy	3,587 +3,574	+27,492%	+$403K	0.09%	139
2019 Q2	$2K	Hold	13	–	–	﹤0.01%	593
2019 Q1	$2K	Sell	13 -100	-88%	-$12.4K	﹤0.01%	577
2018 Q4	$11K	Hold	113	–	–	﹤0.01%	404
2018 Q3	$16K	Hold	113	–	–	0.01%	412
2018 Q2	$14K	Buy	113 +100	+769%	+$11.7K	﹤0.01%	427
2018 Q1	$1K	Hold	13	–	–	﹤0.01%	565
2017 Q4	$2K	Hold	13	–	–	﹤0.01%	441
2017 Q3	$2K	Hold	13	–	–	﹤0.01%	406
2017 Q2	$2K	Buy	+13	New	+$1.51K	﹤0.01%	529

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

BDO Wealth Advisors's ALXN Position: Q3 2021 in Review

BDO Wealth Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 237 shares — an estimated $44K sold.

BDO Wealth Advisors first reported a position in ALXN in Q2 2017 and held it in 17 quarters. The position peaked at $1.66M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

BDO Wealth Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
BDO Wealth Advisors sold 237 Alexion Pharmaceuticals shares in Q3 2021, an estimated $44K.
BDO Wealth Advisors first reported a position in Alexion Pharmaceuticals in Q2 2017 and held it in 17 quarters.
BDO Wealth Advisors's Alexion Pharmaceuticals position peaked at $1.66M in Q4 2020.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on BDO Wealth Advisors's 13F filing for Q3 2021, filed 9 Nov 2021.